DALLAS, March 3, 2015 /PRNewswire/ --
ReportsnReports.com offers Cancer Cachexia - Pipeline Review, H1 2015 research report that provides an overview of the Cancer Cachexia's therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Cancer Cachexia. Cancer Anorexia-Cachexia Syndrome is a multifactorial syndrome that negatively impacts the functional performance, quality of life and prognosis of cancer patients. Cancer cachexia is a wasting syndrome characterized by loss of muscle and fat directly caused by an aberrant host response to cancer. Cancer cachexia is a devastating, multifactorial and often irreversible syndrome that affects around 50-80% of cancer patients. The occurrence of cachexia in cancer patients is dependent on the patient response to tumour progression, including the activation of the inflammatory response and energetic inefficiency involving the mitochondria. The primary cause is related to metabolic changes that take place in response to the host-tumor interaction.
The report has complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dementia and special features on late-stage and discontinued projects.features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Order a Purchase copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=344886 . (This is a premium report priced at US$2000 for a single user License.)
Companies discussed in this report include: Acacia Pharma Ltd., Aeterna Zentaris Inc., Amgen Inc., Aphios Corporation, Atara Biotherapeutics, Inc., Eli Lilly and Company, GTx, Inc., Helsinn Healthcare S.A., Incyte Corporation, Novartis AG, Ohr Pharmaceutical Inc., PsiOxus Therapeutics, Ltd., Radius Health, Inc., RaQualia Pharma Inc., Vicus Therapeutics, LLC.
Drugs profile discussed in this report include: (etodolac + propranolol hydrochloride), (formoterol fumarate + megestrol acetate), anamorelin hydrochloride, Antibody to Inhibit Parathyroid Hormone Related Protein for Cancer Cachexia, Aptamer to Activate Calcineurin A for Genetic Disorders and Musculoskeletal Disorders, ATA-842, bimagrumab, DCB-CA2, dronabinol, Drug to Antagonize ActRIIB for Cancer Cachexia, enobosarm, Espindolol, EXT-400, LY-2495655, macimorelin acetate, NBD Peptide, OHR/AVR-118, RAD-140, RQ-00432933, ruxolitinib phosphate, Small Molecule to Agonize Ghrelin Receptor for Cancer Cachexia and Anorexia, Small Molecule to Inhibit ATGL for Cancer Cachexia and Type 2 Diabetes, Synthetic Peptide to Inhibit Melanocortin Receptor for Cancer Cachexia, Synthetic Peptides for Cancer Cachexia, VK-5211.
Featured News & Press Releases cover by this report include: Oct 30, 2014: New Data on Fatigue from ROMANA 1, a Pivotal Phase III Study of Anamorelin in Advanced NSCLC Patients with Cachexia Presented at 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology; Dec 11, 2013: Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan; Oct 24, 2013: GTx Presents Results from Enobosarm POWER Trials for the Prevention and Treatment of Muscle Wasting in Patients with Non-Small Cell Lung Cancer at 15th World Conference on Lung Cancer; Mar 21, 2013: Ohr Pharma Announces Results From OHR/AVR118 Phase II Trial In Cancer Cachexia; Mar 14, 2013: GTx Announces Publication Of Enobosarm Phase II Trial Results In The Lancet Oncology; Mar 04, 2013: PsiOxus Therapeutics Completes Patient Enrollment For Phase II Wasting Disease Therapeutic MT-102; Oct 08, 2012: GTx To Present Scientific Poster Presentations On Enobosarm At International Society Of Geriatric Oncology; Aug 28, 2012: Aeterna Zentaris Recruits First Patient For Phase IIA Trial In Cancer Cachexia With AEZS-130; Jun 25, 2012: GTx Announces Presentation On Enobosarm's Improvement In Physical Function In Cancer Patients With Both Low And Normal Testosterone Levels; Mar 08, 2012: Michael E. DeBakey Veterans Affairs Medical Center Initiates Phase IIa Trial In Cancer Cachexia With Aeterna Zentaris's Ghrelin Agonist, AEZS-130.
Explore more reports of Global Market Direct Publisher at http://www.reportsnreports.com/publisher/global-markets-direct/ .
Other Related Reports:
Head and Neck Cancer - Pipeline Review, H1 2015
This report provides comprehensive information on the therapeutic development for Head and Neck Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head and Neck Cancer and special features on late-stage and discontinued projects.
Companies discussed in this report include: 3M Drug Delivery Systems, AB Science, Acceleron Pharma, Inc., Advaxis, Inc., Ambrx, Inc., Amgen Inc., arGEN-X BV, ArQule, Inc., Ascenta Therapeutics, Inc., Astellas Pharma Inc., AstraZeneca PLC, AVEO Pharmaceuticals, Inc., Bayer AG, Bexion Pharmaceuticals, LLC., Bio-Path Holdings, Inc., BioDiem Ltd, Bionomics Limited, Biotest AG, Boehringer Ingelheim GmbH, Boston Biomedical, Inc., Bristol-Myers Squibb Company, CEL-SCI Corporation, Celgene Corporation, Cellceutix Corporation, Celldex Therapeutics, Inc., Celltrion, Inc., Centrose Llc, CTI BioPharma Corp., Cyclacel Pharmaceuticals, Inc., CytomX Therapeutics, Inc., Daewoong Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, EcoBiotics Limited, Eisai Co., Ltd., Eli Lilly and Company, EntreChem, S.L., Etubics Corporation, F. Hoffmann-La Roche Ltd., Genelux Corporation, Genentech, Inc., Genexine, Inc., Genmab A/S, GlaxoSmithKline plc, Gliknik, Inc., Glycotope GmbH, Green Cross Corporation, ImmunoGen, Inc., Immunomedics, Inc., Immunovative Therapies, Ltd., Incuron, LLC, Incyte Corporation, Innate Pharma SA, Inovio Pharmaceuticals, Inc., InteRNA Technologies B.V., ISU ABXIS Co.,Ltd., Jiangsu Kanion Pharmaceutical Co., Ltd., Karyopharm Therapeutics, Inc., Laboratoires Pierre Fabre SA, Lytix Biopharma AS, Mabion SA, MacroGenics, Inc., Marsala Biotech Inc.
ReportsnReports.com is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. We provide reports by 100+ publishers on a range of categories and industries.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect with Us:
G+ / Google Plus: https://plus.google.com/u/0/111656568937629536321/posts
RSS / Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml